Tirzepatide is the first single-molecule dual agonist of the GIP and GLP-1 receptors to move through a large late-stage clinical program. This review summarizes, in third person and for research context only, what the published SURPASS and SURMOUNT trials and the underlying pharmacology literature actually report.

A dual-incretin molecule, not another GLP-1 analog

Most incretin-based compounds studied over the past two decades act on a single target: the glucagon-like peptide-1 (GLP-1) receptor. Tirzepatide, originally designated LY3298176, was designed to be structurally distinct. According to the discovery-to-proof-of-concept report published in Molecular Metabolism, it is a fatty-acid-modified 39-amino-acid peptide engineered so that one molecule binds and activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor.¹ The acylation extends its circulating half-life enough to support once-weekly subcutaneous administration in the trial protocols.¹

The scientific rationale was that GIP and GLP-1 are both native incretin hormones released after eating, and that engaging both receptor systems simultaneously might produce metabolic signals that single-receptor agonism does not. In the original Phase 1 work, the molecule activated both receptors in cell-based assays and improved glucose tolerance in mice; early human data showed dose-dependent reductions in fasting glucose and body weight, with gastrointestinal events as the most common tolerability finding.¹ That preclinical-to-clinical translation is what justified the subsequent large SURPASS and SURMOUNT programs discussed below. Researchers comparing incretin classes often benchmark tirzepatide against selective GLP-1 agonists such as semaglutide.

How the dual GIP/GLP-1 mechanism is thought to work

The GLP-1 arm of tirzepatide's activity is comparatively well characterized from the broader incretin literature: GLP-1 receptor signaling is associated with glucose-dependent insulin secretion, suppression of glucagon, slowed gastric emptying and reduced food intake. The GIP arm is where the mechanistic picture is less settled, and much of what is known comes from animal models rather than human tissue.

What the rodent studies suggest about the GIP contribution

Work published in the Journal of Clinical Investigation used obese wild-type and GLP-1-receptor-knockout mice to isolate the GIP receptor's role. In that model tirzepatide improved insulin sensitivity partly independently of weight loss, and a long-acting GIP-receptor agonist reproduced part of the effect by enhancing glucose disposal in white adipose tissue.² A companion study reported that tirzepatide shifted branched-chain amino acid handling and induced a thermogenic-like metabolite signature in brown adipose tissue of diet-induced obese mice.³ These are mechanistically interesting findings, but they are rodent data and should be read as hypotheses about the human mechanism rather than established human physiology.²

The practical framing for researchers is that tirzepatide's downstream readouts in humans — lower HbA1c and reduced body weight in the trials — are robustly documented, whereas the precise apportioning of those readouts between the GIP and GLP-1 receptors is still being worked out in preclinical systems. This distinction matters when designing mechanism-focused experiments rather than simply replicating clinical endpoints.

What the SURPASS diabetes trials reported

The SURPASS program evaluated glycemic endpoints in adults with type 2 diabetes. In SURPASS-1, a 40-week placebo-controlled monotherapy trial, participants randomized to tirzepatide showed HbA1c reductions of roughly 1.9 to 2.1 percentage points across the 5, 10 and 15 mg arms versus a negligible change on placebo, alongside dose-dependent body-weight reductions of approximately 7 to 9.5 kg.⁴ No clinically significant or severe hypoglycemia was reported with tirzepatide in that trial, consistent with the glucose-dependent nature of incretin signaling.⁴

SURPASS-2 provided a head-to-head comparison against a selective GLP-1 receptor agonist. In this open-label 40-week trial of 1,879 participants, all three tirzepatide doses lowered HbA1c more than 1 mg semaglutide, with estimated treatment differences of -0.15, -0.39 and -0.45 percentage points for the 5, 10 and 15 mg doses; tirzepatide met both non-inferiority and superiority criteria for the glycemic endpoint, and body-weight reductions were larger than with semaglutide.⁵ The comparison is often cited because it is one of the few active-controlled datasets directly contrasting a dual agonist against an established single-receptor agonist.⁵

What the SURMOUNT obesity trials reported

Where SURPASS focused on glycemic control, the SURMOUNT program measured body-weight endpoints. SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight with a weight-related complication, and specifically excluded diabetes. Over 72 weeks, mean weight change was -15.0% at 5 mg, -19.5% at 10 mg and -20.9% at 15 mg, versus -3.1% on placebo, from a mean baseline weight of 104.8 kg.⁶ At the two higher doses, roughly half to just over half of participants recorded a body-weight reduction of 20% or more, compared with 3% on placebo.⁶

SURMOUNT-2 extended the question to adults living with both obesity and type 2 diabetes. The reductions in that population were clinically meaningful but smaller in magnitude than in the diabetes-free SURMOUNT-1 cohort, a pattern consistent with earlier observations that weight response to incretin therapy tends to be attenuated in the presence of type 2 diabetes.⁷ Taken together, the SURMOUNT data are the basis for describing tirzepatide's weight effect as dose-dependent and population-dependent rather than uniform.

For laboratory groups modeling comparative incretin pharmacology, the trial doses reported here describe how the compound was administered in the studies; they are not guidance for any human use. Adjacent research interest has extended to next-generation multi-receptor peptides such as the triple agonist retatrutide, which adds glucagon-receptor activity to the incretin mechanism.

Tolerability signals in the trial record

Across the SURPASS and SURMOUNT trials, the adverse-event profile was dominated by gastrointestinal symptoms — nausea, diarrhea, vomiting, constipation and reduced appetite — and these were consistently dose-related.⁴⁶ Several features recur across the reports:

Timing and severity

Most gastrointestinal events were characterized as mild to moderate and clustered during the dose-escalation phase, tending to diminish thereafter. Trial protocols used gradual titration over multiple weeks, and the reports link that titration to the observed tolerability pattern.⁶

Discontinuation

Study-drug discontinuation attributable to adverse events was documented in each trial and generally increased with dose, but the trials were not designed to establish long-term tolerability beyond their defined follow-up windows.⁴ As with any peptide research compound, degradation, handling and reconstitution variables can independently affect experimental readouts and should be controlled separately from any pharmacological interpretation.

Liver and cardiovascular research directions

Beyond glucose and weight endpoints, tirzepatide has been examined in adjacent metabolic contexts. A Phase 2 dose-finding trial published in the New England Journal of Medicine studied participants with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis. Resolution of MASH without worsening of fibrosis at 52 weeks was reported in 44%, 56% and 62% of the 5, 10 and 15 mg groups versus 10% on placebo — a Phase 2 signal that the authors describe as warranting larger confirmatory study rather than a definitive conclusion.⁸

On cardiovascular outcomes, the dedicated SURPASS-CVOT was designed as an active-controlled trial comparing tirzepatide against dulaglutide, a GLP-1 receptor agonist with an established cardiovascular dataset, rather than against placebo.⁹ That design choice reflects a deliberately conservative framing: the earlier efficacy trials did not surface a cardiovascular safety signal, but a purpose-built outcome trial is the appropriate instrument for cardiovascular questions, and its methodology paper is explicit that such conclusions require the dedicated study.⁹ Researchers should treat cardiovascular and hepatic findings as evolving rather than settled.

Evidence level, regulatory status and open questions

The human efficacy data for glycemic control and body weight come from large, randomized, controlled Phase 3 trials — a comparatively strong evidence tier.⁵⁶ The mechanistic account of how the GIP receptor contributes, by contrast, leans heavily on rodent and in-vitro work and remains an open question.²³ The MASH data are Phase 2, and long-term cardiovascular outcomes are the subject of a dedicated trial rather than an established result.⁸⁹ Open questions that recur in the literature include the durability of weight change after discontinuation, body-composition effects, and how much of the metabolic response is receptor-specific.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.